Back

Is the polypill effective in primary prevention? The evidence.

7 April 2017 (16:52 - 17:15)
Organised by:
Congress Presentation Part of: The cardiovascular polypill: practical implementation Miscellaneous Open Access EuroPrevent 2017

About the speaker

Photo
Doctor Melvin Lafeber

University Medical Center Utrecht, Utrecht (Netherlands (The))

3 More presentations in this session

Presentation thumbnail
Rationale for the use of the polypill in cardiovascular disease.
Professor D. Grobbee (Utrecht, NL)
Slides Video
Presentation thumbnail
Is the polypill effective in secondary prevention? The evidence.
Professor V. Barrios (Madrid, ES)
Slides Video
Presentation thumbnail
Practical implementation of the polypill, current status and future challenges.
Professor J. Gonzalez Juanatey (Santiago de Compostela, ES)
Slides Video

Access the full session

Session thumbnail
The cardiovascular polypill: practical implementation

The Event

Event poster

EuroPrevent 2017

7 April 2017 16:52 CET
You may be interested in
thumbnail
Congress Presentation
3 September 2019
thumbnail
Congress Presentation
Outcomes of diabetic patients with acute coronary syndromes treated with aspirin in primary prevention
28 August 2023
thumbnail
Congress Presentation
The patient behind the fourth drug question
29 August 2026
thumbnail
Congress Presentation
The CV polypill strategy (acetyl salicylic acid + atorvastatin + ramipril) as baseline treatment after a cardiovascular event supported by recent compelling evidence: a global expert consensus
25 April 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources